Display options
Cite
Nerich V, Guyeux C, Henry-Amar M, et al. Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2021;doi: 10.1002/cncr.33938.
Nerich, V., Guyeux, C., Henry-Amar, M., Couturier, R., Thieblemont, C., Ribrag, V., Tilly, H., Haioun, C., Casasnovas, R. O., Morschhauser, F., Feugier, P., Sibon, D., Ysebaert, L., Nicolas-Virelizier, E., Broussais-Guillaumot, F., Damaj, G. L., Jais, J. P., Salles, G., Woronoff-Lemsi, M., & Mounier, N. (2021). Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer, . https://doi.org/10.1002/cncr.33938
Nerich, Virginie, et al. "Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33938
Nerich V, Guyeux C, Henry-Amar M, Couturier R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Sibon D, Ysebaert L, Nicolas-Virelizier E, Broussais-Guillaumot F, Damaj GL, Jais JP, Salles G, Woronoff-Lemsi M, Mounier N. Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2021 Oct 04; doi: 10.1002/cncr.33938. Epub 2021 Oct 04. PMID: 34605020.
Copy Download .nbib Format: NLM
Share it on

Cancer. 2021 Oct 04; doi: 10.1002/cncr.33938. Epub 2021 Oct 04.

Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.

Cancer

Virginie Nerich, Christophe Guyeux, Michel Henry-Amar, Raphaël Couturier, Catherine Thieblemont, Vincent Ribrag, Hervé Tilly, Corinne Haioun, René-Olivier Casasnovas, Franck Morschhauser, Pierre Feugier, David Sibon, Loic Ysebaert, Emmanuelle Nicolas-Virelizier, Florence Broussais-Guillaumot, Gandhi L Damaj, Jean-Philippe Jais, Gilles Salles, Macha Woronoff-Lemsi, Nicolas Mounier

Affiliations

  1. Department of Pharmacy, University Hospital, Besançon, France.
  2. INSERM, EFS-BFC, UMR1098, University of Franche-Comté, Besançon, France.
  3. Femto-ST Institute, UMR 6174 CNRS, University of Bourgogne Franche-Comté, Besançon, France.
  4. French Center on eHealth, North-West Region Data Processing Center and French National League Against Cancer Clinical Research Platform, CCC François Baclesse, Caen, France.
  5. Hemato-Oncology Unit, Saint-Louis University Hospital Center, Public Hospital Network of Paris, Paris, France.
  6. Hematology Unit, Gustave Roussy Cancer Campus, Villejuif, France.
  7. Hematology Department and French Institute of Health and Medical Research Unit 1243, Henri Becquerel Center, Rouen, France.
  8. Lymphoid Malignancies Unit, Henri Mondor University Hospital Center, Public Hospital Network of Paris, Créteil, France.
  9. Hematology Unit and French Institute of Health and Medical Research Unit 1231, Bocage Hospital, Dijon Bourgogne Regional University Hospital Center, Dijon, France.
  10. Hematology Transfusion Institute, Claude Huriez Hospital, Lille Regional University Hospital Center, Lille, France.
  11. Hematology Unit, Brabois Hospital, Nancy University Hospital Center, Vandoeuvre-lès-Nancy, France.
  12. Hematology Unit, Necker University Hospital for Sick Children, Public Hospital Network of Paris, Paris, France.
  13. Oncopole, Toulouse University Cancer Institute, Toulouse, France.
  14. Hematology Unit, Léon Bérard Center, Lyon, France.
  15. Clinical Research Department-Lymphoma Study Association, Lyon South Hospital Center, Pierre-Bénite, France.
  16. Basse-Normandy Hematology Institute, Côte de Nacre Regional University Hospital Center, Caen, France.
  17. Laboratory of Biostatistics, Paris V University-Descartes, Paris, France.
  18. Faculty of Medicine, Claude Bernard University, Lyon, France.
  19. Hematology Department, Lyon South Hospital Center, Pierre-Bénite, France.
  20. Department of Clinical Research and Innovation, University Hospital, Besançon, France.
  21. Onco-Hematology Unit, l'Archet Hospital, Nice University Hospital Center, University of Côte d'Azur, Nice, France.

PMID: 34605020 DOI: 10.1002/cncr.33938

Abstract

BACKGROUND: No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors.

METHODS: Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs.

RESULTS: In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs.

CONCLUSIONS: The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person-centered health care pathways.

© 2021 American Cancer Society.

Keywords: cancer survivors; explanatory factors; health care cost; health care resource use; non-Hodgkin lymphoma; rituximab

References

  1. French National Cancer Institute Accessed May 19, 2021. https://en.e-cancer.fr/ - PubMed
  2. Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011;96:1136-1143. doi:10.3324/haematol.2010.038109 - PubMed
  3. Younes A, Ansell S, Fowler N, et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017;14:335-346. doi:10.1038/nrclinonc.2016.205 - PubMed
  4. Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076-1088. doi:10.1016/S1470-2045(17)30444-8 - PubMed
  5. Boulat T, Ghosn W, Morgand C, Falissard L, Roussel S, Rey G. Principales évolutions de la mortalité par cause sur la période 2000-2016 en France métropolitaine. Bull Epidémiol Hebd. 2019;29-30:576-584. - PubMed
  6. Améliorer la qualité du système de santé et maîtriser les dépenses. L'Assurance Maladie. Accessed May 19, 2021. https://www.ameli.fr/sites/default/files/rapport-charges-et-produits-2020.pdf - PubMed
  7. Burudpakdee C, Lin HM, Wang W, et al. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. J Med Econ. 2016;19:965-972. doi:10.1080/13696998.2016.1187622 - PubMed
  8. Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59:1133-1142. doi:10.1080/10428194.2017.1375100 - PubMed
  9. Albarmawi H, Nagarajan M, Sun K, et al. Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data. Leuk Lymphoma. 2020;61:75-83. doi:10.1080/10428194.2019.1648804 - PubMed
  10. Foster T, Miller JD, Boye ME, Russell MW. Economic burden of follicular non-Hodgkin's lymphoma. Pharmacoeconomics. 2009;27:657-679. doi:10.2165/11314820-000000000-00000 - PubMed
  11. Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2019;19:645-661. doi:10.1080/14737167.2019.1680288 - PubMed
  12. Kutikova L, Bowman L, Chang S, Long SR, Arning M, Crown WH. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006;47:1535-1544. doi:10.1080/10428190600573325 - PubMed
  13. Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J. Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care. 2016;54:343-349. doi:10.1097/MLR.0000000000000486 - PubMed
  14. Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012;2012:978391. doi:10.1155/2012/978391 - PubMed
  15. Beveridge R, Satram-Hoang S, Sail K, et al. Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52:2117-2123. doi:10.3109/10428194.2011.592623 - PubMed
  16. Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14:2627-2642. doi:10.2217/fon-2018-0267 - PubMed
  17. Muneishi M, Nakamura A, Tachibana K, et al. Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics. Int J Clin Oncol. 2018;23:375-381. doi:10.1007/s10147-017-1202-2 - PubMed
  18. Monga N, Nastoupil L, Garside J, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98:175-183. doi:10.1007/s00277-018-3501-8 - PubMed
  19. Yang X, Laliberté F, Germain G, et al. Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S. Oncologist. 2021;26:e817-e826. doi:10.1002/onco.13721 - PubMed
  20. Mounier N, Anthony S, Busson R, et al. Long-term fatigue in survivors of non-Hodgkin lymphoma: the Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2019;125:2291-2299. doi:10.1002/cncr.32040 - PubMed
  21. ATC classification system: structure and principles. WHO Collaborating Centre for Drug Statistics Methodology. Accessed May 19, 2021. https://www.whocc.no/atc/structure_and_principles/ - PubMed
  22. Choices in Methods for Economic Evaluation. French National Authority for Health. Accessed May 19, 2021. https://www.has-sante.fr/jcms/r_1499251/en/choices-in-methods-for-economic-evaluation - PubMed
  23. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-494. doi:10.1016/s0167-6296(01)00086-8 - PubMed
  24. Yvonne M, Bishop Y, Fienberg S, Holland P. Discrete Multivariate Analysis Theory and Practice. Springer; 2007. - PubMed
  25. You CH, Kang S, Kwon YD. The economic burden of breast cancer survivors in Korea: a descriptive study using a 26-month micro-costing cohort approach. Asian Pac J Cancer Prev. 2019;20:2131-2137. doi:10.31557/APJCP.2019.20.7.2131 - PubMed
  26. Zhang X, Liu S, Liu Y, et al. Economic burden for lung cancer survivors in urban China. Int J Environ Res Public Health. 2017;14:308. doi:10.3390/ijerph14030308 - PubMed
  27. Barrows CE, Belle JM, Fleishman A, Lubitz CC, James BC. Financial burden of thyroid cancer in the United States: an estimate of economic and psychological hardship among thyroid cancer survivors. Surgery. 2020;167:378-384. doi:10.1016/j.surg.2019.09.010 - PubMed
  28. Massa ST, Osazuwa-Peters N, Adjei Boakye E, Walker RJ, Ward GM. Comparison of the financial burden of survivors of head and neck cancer with other cancer survivors. JAMA Otolaryngol Head Neck Surg. 2019;145:239-249. doi:10.1001/jamaoto.2018.3982 - PubMed

Publication Types

Grant support